Navigation Links
CoolGard 3000 Thermal Regulation System

ProductsCoolGard 3000 Thermal Regulation System
Company Alsius Corporation
Item CoolGard 3000 Thermal Regulation System
Features 
Description All Alsius heat exchange catheters connect to the CoolGard 3000 Thermal Regulation System, which achieves and maintains a target temperature input by the user. It remotely senses changes in patient core temperature and automatically adjusts the temperature of the circulating saline within the catheter (0-42C), providing consistent maintenance of temperature. The CoolGard 3000 represents a powerful platform for current and future temperature management therapies as they are developed
Info Alsius Corporation
Customer Service: (949) 453-0150
Web site: http://www.alsius.com

Related medicine products :

1. iEMS Thermal Holder HT
2. Thermal Seal, Clear
3. ThermalSeal (non-sterile)
4. ThermalSeal RT Optically Clear Adhesive Plate Film (2mil)
5. ThermalSeal RT Optically Clear Adhesive Plate Film (5mil)
6. ThermalSeal (sterile)
7. Exicycler™ Real-time Thermal Block
8. iCycler Thermal Cycler
9. Gene Cycler Thermal Cycler
10. PCR Sprint Thermal Cycler
11. Px2 Thermal Cycler Chassis
... PreVue B. Burgdorferi Antibody Detection Assay is ... the qualitative presumptive (first step) detection of ... in human serum or whole blood. Rapid ... accuracy make the Wampole PreVue B. burgdorferi ...
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
Medicine Products:
(Date:7/30/2014)... The Technology Association of Georgia in collaboration ... today issued its final call for applications and nominations ... have until August 29th 2014 to be considered for ... by the Excalibur Judging Committee. Companies selected as semi-finalists ... for interviewing process. , The TAG Excalibur Awards ...
(Date:7/30/2014)... 2014 The Ehlers-Danlos National Foundation (EDNF) ... Sandra Aiken Chack will serve as chair. The board ... 2014 Annual Learning Conference in Houston, Texas July 10-12. ... agenda ahead of us. From the rollout of the ... the Greater Baltimore Medical Center to our September physicians ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 Over ... Chao Pinhole Surgical Technique®, the revolutionary minimally invasive treatment ... Shanelec, considered by many of his peers to be ... guest speaker at a recent Chao Pinhole Surgical Technique® ... CA. Dr. Shanelec is the recipient of the American ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help ... Instant Quote tool on its website, LTCconsumer.com , announced ... are free and unlimited. , The Instant Quote tool ... including age, gender, and state of residence – and delivers ... to enter any contact information to get started). There is ...
(Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
Breaking Medicine News(10 mins):Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... Clemson University researcher Julia Frugoli has received $132,769 as ... from the National Science Foundation to continue her study ... other to control their growth and development. The ... College of Agriculture, Forestry & Life Sciences, genetics and ...
... , MONDAY, May 14 (HealthDay News) -- In black ... arteries in the eye,s retina (retinal arteriolar narrowing) is ... study finds. , "Retinal arteriolar narrowing has long been ... hypertension [high blood pressure] and cardiovascular disease," Dr. Monique ...
... Philadelphia, PA, May 14, 2012 Health professionals commonly say, ... but is there any scientific basis for the advice? ... your past experience with needle pricks, along with information you ... is published in the May issue of Pain . ...
... A new type of artificial eye system could one day ... to degenerative eye diseases such as macular degeneration, according to ... tiny solar panel-like cells that are surgically placed beneath the ... with a miniature camera, and a pocket PC that processes ...
... examining the effects of resveratrol on individuals with mild ... as more than two dozen academic institutions recruit volunteers ... Ph.D., director of Georgetown University Medical Center,s Memory Disorders ... Resveratrol is a compound found in red grapes, ...
... (HealthDay News) -- Doing more repetitions with less weight ... training with heavy weights, a new Canadian study indicates. ... yourself to the point of fatigue, according to the ... examined how different combinations of weight loads and repetitions ...
Cached Medicine News:Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2Health News:To avoid pain during an injection, look away 2Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 3Health News:With Weights, You Can Lighten Your Load 2
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7